索磷布韦联合利巴韦林治疗基因2型丙型肝炎病毒感染合并肝硬化患者:真实世界经验
该意大利真实世界队列评估了291例基因2型丙型肝炎病毒(HCV GT2)感染伴桥接纤维化或肝硬化患者接受索磷布韦(SOF)联合基于体重利巴韦林(RBV)治疗的持续病毒学应答(SVR12)。总体SVR12为95.53%,非肝硬化患者为99.15%,肝硬化患者为93.06%;完成治疗者中肝硬化患者SVR率为94.51%,16周或20周方案分别为94.94%。低血小板计数和食管静脉曲张是SVR的预测因素。
要点
- SOF/RBV治疗16或20周在真实世界中使GT2肝硬化患者获得约95%的SVR12。
- 总体SVR12为95.53%,非肝硬化99.15%,肝硬化93.06%。
- 低血小板计数(OR 7.2)和食管静脉曲张(OR 0.1)是SVR预测因素。
核心结论
- 在GT2肝硬化患者中,SOF/RBV治疗16或20周与真实世界SVR12率约95%相关。
研究设计与样本
- 意大利真实世界队列研究,评估291例HCV GT2感染伴桥接纤维化或肝硬化患者。
- 中位年龄68岁(范围18-87),163例为初治患者。
- 168例肝硬化患者中,149例Child-Pugh A级,19例B级;50例血小板计数<100,000/mm3,62例白蛋白<3.5g/dl。
主要发现
- 总体SVR12为95.53%,非肝硬化患者为99.15%,肝硬化患者为93.06%。
- 完成治疗的肝硬化患者SVR率为94.51%,16周或20周方案分别为94.94%。
- SVR预测因素:低血小板计数(OR 7.2;95% CI 1.67-31.25;p=0.0022)和食管静脉曲张(OR 0.1;95% CI 0.01-0.72;p=0.0079)。
- 贫血轻度12.4%、中度3.4%、重度2.4%;较长疗程贫血略更常见,但与治疗中断无关。
- 复发时未鉴定出2k/1b嵌合株或与基线不同的基因型。
临床怎么用
- 作者指出,在GT2肝硬化患者中SOF/RBV治疗16或20周与真实世界SVR12率约95%相关。
- 作者提及该联合方案近期已被索磷布韦/维帕他韦固定剂量复方替代作为HCV GT2治疗标准,但本研究结果可能为尚未获得新方案的国家提供参考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Sofosbuvir (SOF) and weight-based ribarivin (RBV) represented until recently the standard of care in hepatitis C virus (HCV) genotype (GT)2 patients. In registration studies 12-16weeks duration were associated with a 90% sustained virological response at 12weeks (SVR12). Real life cohorts showed lower SVR12 rates. METHODS: SVR12 rates attained in an Italian real life cohort and possible benefits of a duration extended up to 20weeks was investigated in HCV GT2 patients with cirrhosis. The role of 2k/1b chimeras as potential predictor of treatment failure was also analysed. RESULTS: Overall, 291 HCV GT2 infected patients with bridging fibrosis or cirrhosis were evaluated. Median age was 68years (18-87); 163 were treatment naïve. Of 168 cirrhotic patients, 149 had Child-Pugh score A and 19 B, 50 platelets count <100,000/mm3 and 62 albumin <3.5g/dl. SVR12 were 95.53% overall, with 99.15% in non-cirrhotic patients and 93.06% in cirrhotic patients. In patients who completed treatment, SVR rates for cirrhotic patients resulted in 94.51%, and 94.94% after 16 or 20weeks respectively. Predictors of SVR were low platelet count and esophageal varices (OR 7.2; 95% CI 1.67-31.25; p=0.0022 and OR 0.1; 95% CI 0.01-0.72; p=0.0079, respectively). Anemia was mild in 12.4%, moderate in 3.4%, and severe in 2.4% of cases. Anemia was slightly more frequent among longer duration but not associated with treatment discontinuations. No 2k/1b strains or genotypes different from those at baseline were identified at relapse. CONCLUSIONS: In GT2 cirrhotic patients, SOF/RBV for 16 or 20weeks is associated with real life SVR12 rates of 95%. LAY SUMMARY: A duration of treatment of 16-20weeks was recommended for treatment of HCV GT2 patients using the combination of sofosbuvir and ribavirin. Real life experiences, where patients received 12weeks of treatment regardless of the severity of liver disease, suggested that response rates are lower than expected, in particular in patients with liver cirrhosis. A misleading genotyping of a 2k/1b strain as GT2 was also hypothesized as a further explanation for less effectiveness. We demonstrated that using the recommended extended duration in patients with more severe disease 95% of patients with severe liver disease including cirrhosis can be cured and that 2k/1b strain plays only a secondary role in specific countries like Germany. Although this combination has been recently replaced by sofosbuvir and velpatasvir fixed dose combination as the standard of care for treating HCV GT2 patients, our findings may inform physicians from countries where the new regimen is not yet available.
引用
- Mangia A, Susser S, Piazzolla V, et al. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience. J Hepatol. 2016. PMID: 27965158. doi:10.1016/j.jhep.2016.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。